cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Royalty Pharma Plc
9 own
17 watching
Current Price
$27.35
$0.28
(1.03%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
16,338.93M
52-Week High
52-Week High
44.47000
52-Week Low
52-Week Low
25.92000
Average Volume
Average Volume
3.34M
Dividend Yield
Dividend Yield
0.020496
P/E Ratio
P/E Ratio
24.6959
iconMarket Capitalization16,338.93M
icon52-Week High44.47000
icon52-Week Low25.92000
iconAverage Volume3.34M
iconDividend Yield0.020496
iconP/E Ratio24.6959
What does the Royalty Pharma Plc do?
N/A
Read More
How much money does Royalty Pharma Plc make?
News & Events about Royalty Pharma Plc.
Globe Newswire
7 months ago
NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. ...
Globe Newswire
8 months ago
Royalty Pharmas founder and Chief Executive Officer, Pablo Legorreta, has also indicated that he intends to purchase up to an additional $50 million of the companys Class A ordinary shares NEW YORK, March 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that the ...
Business Wire
8 months ago
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, and Royalty Pharma (Nasdaq: RPRX), the largest buyer of biopharmaceutical royalties and a...
Globe Newswire
8 months ago
Royalty Pharma now expects 2023 Adjusted Cash Receipts(1) (non-GAAP) to be between $2,850 million and $2,950 million, excluding contributions from future transactions NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has received a $475 million ...
Globe Newswire
9 months ago
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Ashwin Pai, M.D. as Executive Vice President, Investments. Ashwin will join Royalty Pharma in April 2023, and will report to Chris Hite, Executive Vice President and Vice Chairman. ...
Frequently Asked Questions
Frequently Asked Questions
What is Royalty Pharma Plc share price today?
plus_minus_icon
Can Indians buy Royalty Pharma Plc shares?
plus_minus_icon
How can I buy Royalty Pharma Plc shares from India?
plus_minus_icon
Can Fractional shares of Royalty Pharma Plc be purchased?
plus_minus_icon
What are the documents required to start investing in Royalty Pharma Plc stocks?
plus_minus_icon
What is today’s traded volume of Royalty Pharma Plc?
plus_minus_icon
What is today’s market capitalisation of Royalty Pharma Plc?
plus_minus_icon
What is the 52-Week High and Low Range of Royalty Pharma Plc?
plus_minus_icon
What percentage is Royalty Pharma Plc down from its 52-Week High?
plus_minus_icon
What percentage is Royalty Pharma Plc up from its 52-Week Low?
plus_minus_icon
Current Price
$27.35
$0.28
(1.03%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$68.00
$0.55 (0.82 %)
Viking Therapeutics, Inc.
Viking Therapeutics, Inc.
$13.01
$0.79 (6.46 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.03
$-0.02 (-0.98 %)
Cymabay Therapeutics Inc
Cymabay Therapeutics Inc
$19.70
$0.57 (2.98 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$68.00
$0.55 (0.82 %)
Viking Therapeutics, Inc.
Viking Therapeutics, Inc.
$13.01
$0.79 (6.46 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.03
$-0.02 (-0.98 %)
Cymabay Therapeutics Inc
Cymabay Therapeutics Inc
$19.70
$0.57 (2.98 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00